$MRK news
The latest MRK stock news: headlines, filings, AI summaries and sentiment for $MRK, updated around the clock.
- Moderna Plans to Use Massachusetts Facility as Global Supply Hub for Cancer Vaccine
- Moderna's Revenue Growth Driven by COVID Products Raises Valuation Concerns
- Merck's Efinopegdutide Meets Primary Endpoint in Phase 2b MASH Clinical Trial
- Moderna Upgrades 2026 Revenue Guidance Following Positive Phase 3 Cancer Vaccine Results
- Moderna Reports Third Quarter Profit Driven by Reduced R&D Spending
- Moderna Reports Surprise Third-Quarter Profit and Raises Full-Year Revenue Guidance
- Market Outlook: Strong Jobs Data, Tech Volatility, and Key Earnings Results
- Halozyme Reports Strong Q3 2026 Results with Significant Revenue Growth and Raised Guidance
- Gilead Sciences Maintains 11-Year Dividend Growth Streak Supported by HIV and Oncology Revenue
- Merck & Co., Inc. - 10-Q Filing
- Major US Indexes and Biotech Sector Rally Following Election and Strong Earnings
- FDA Grants Emergency Use Authorization for Merck's Bravecto to Treat Screwworm Infestations
- Moderna and Merck Face Manufacturing Challenges for Promising Personalized Cancer Vaccine
- Genmab Shares Double Following Three Successful Phase 3 Cancer Drug Trials
- Securitize Expands Onchain U.S. Equity Offering to 25 Stocks via Solana
- Weekly Healthcare Market Update: Focus on Eli Lilly, Merck, and AstraZeneca Amid Broad Market Decline
- Merck Shares Rise Following Strong Third-Quarter Earnings and Analyst Upgrades
- Merck Reports Q3 2026 Results with $18.1 Billion in Sales and Raised Full-Year Guidance
- Merck Raises Full-Year Outlook as New Drug Sales Offset Generic Losses
- Merck Projects 2026 Revenue Between $66.8B and $67.3B Amid Keytruda Transition Strategy
- Merck Reports Q3 Earnings Beat Driven by Keytruda and Gardasil Growth
- Merck Exceeds Q3 Earnings Estimates and Raises 2026 Profit Outlook
- Merck & Co., Inc. - 8-K Filing
- Merck Exceeds Third-Quarter Estimates and Raises Profit Outlook Driven by Keytruda Sales
- Major Corporate Earnings Reports Scheduled Before Market Open on Thursday
- Merck and Eli Lilly Prepare for Third-Quarter Earnings Reports
- Genmab Shares Surge Following Positive Phase 3 Trial Results for Petosemtamab
- AstraZeneca Explores Development of mRNA Cancer Vaccines
- Moderna Shares Decline Following William Blair Downgrade
- Moderna CEO Expresses Confidence in Personalized Cancer Vaccine Expansion Beyond Melanoma
- Merck's sacituzumab tirumotecan Reduces Death Risk by 32% in Endometrial Cancer Phase 3 Trial
- ESMO Congress Highlights Oncology Breakthroughs Amid Market Volatility and Fed Uncertainty
- European Commission Approves Merck and Pfizer/Astellas Combination Therapy for Bladder Cancer
- Moderna's mRNA Pipeline Expansion Drives Growth Potential Beyond COVID-19 Vaccines
- Merck and AbbVie: Two High-Performing Dividend Stocks in Healthcare
- Merck CEO Expresses Confidence in Improving Manufacturing Efficiency for Cancer Vaccine with Moderna
- Merck & Co., Inc. - 8-K Filing
- Moderna's Market Cap Surpasses BioNTech by Over Three Times Amid Diverging Biotech Pipelines
- Merck's Experimental Eye Drug Shows Efficacy in Trial but Raises Safety Concerns
- Moderna Stock Surges Over 14% on New Cancer Research Initiative
- Dutch Court Bans Merck's Injectable Version of Keytruda in Certain European Markets
- Tempus AI Expands Cancer Therapy Collaboration with Moderna and Merck
- Halozyme Wins Dutch Patent Infringement Case Against Merck's Keytruda SC
- AstraZeneca CEO Discusses Summit Therapeutics' Drug as a Potential Game-Changer for Cancer Treatment
- Stocks Making Significant Moves Midday: Microsoft, SpaceX, Vaxcyte, Banco Bradesco, DraftKings Among Others
- Vaxcyte Shares Rise on Positive Phase 3 Data for Pneumonia Vaccine Candidate
- Moderna Stock Surges Amid Positive Cancer Vaccine News
- Merck Reports Positive Mid-Stage Trial Results for Hidradenitis Suppurativa Drug
- Citi Downgrades Moderna to Sell Amid Concerns Over Stock Valuation
- Moderna Stock Surges Over 550% Amid Cancer Vaccine Hype; Is It Too Late to Buy?